I meant to include this article, a 24 Nov 2023 news release on Terbium-161, in a followup reply to Marnie's post of the Dr. Morgan interview by the excellent PeterMac team several days back.
Three big challenges in metastatic prostate cancer | Dr Alicia Morgans
In the interview it was obvious Dr. Morgans was enthusiastic about the early results from the clinical trial on Terbium-161 now underway in AU. She even referred to it's impact on the destruction of cancer cells as having been described being "like a firecracker in the cell". (Her comments are at around 35:30 in the podcast.) I say bring on the firecrackers, "tin cans", and "cherry bombs" . . . I'll take one of each.
Here is the link to the EurekAlert! article:
Terbium-161: new radionuclide for targeted cancer therapy hits the clinic: Highly targeted cancer treatment has the potential to eliminate ultra-small cancer lesions that cause disease recurrence, Business Announcement, Paul Scherrer Institute, News Release 24-Nov-2023
Thanks for posting.... Another interesting radioligand... Terbium-161-- better uptake than Lu-177 and capable of wiping out micrometastasis per the materials (Oh my goodness)...at least appears so in preclinical trials...
The question is does it do better for nodal disease or bone disease ?? Lu-177 is better in nodal disease.
One can not be a shrinking violet when participating in the VIOLET trial.. The Phase I/II will give us some ideas about tolerance, dosing, and how this stacks up as a treatment for MCRPC and NEPC. It will include looking at patients with no prior radioisotope exposure, and look at PFS, rPFS and OS in a single arm trial.. (If you're up against the wall....well why not??)
For MCRPC patients in Oz, and Moffitt folks, it will be an opportunity to have an alternative treatment. The beauty of radioligand development and in Oz is that it is faster than a new drug development here...
That Science... like a freight train....will run down that varmint PCa... Count on it !!!
Apparently, there are a whole slew of radioligands in development, alpha and beta-based. Over time we may see a menu listing of them that can be tailored to patient proflies and disease state. However, we will need for the precision testing costs to come down, as you have mentioned, for the matching to be effective. Right now it is often target-shooting hit-or-miss at best.
It is also unreasonable that walk-it PSMA treatments in AU are done at something close to 10% of the cost for Pluvicto (non-insurance covered) here in the US. Prasad has it right when he says our exoribant drug costs amounts to a wealth transfer to the drug comapnies and their stockholders from the patients and their families.
The radioligand industry is in its infancy, like much of the oncological developments in prostate cancer, as well as other cancers. Yes, I can see a time, where based on precision testing, you will get this radioligand based on genetic testing and location (nodal, skeletal, mixed, or visceral), and will get this number of doses based on tumor sizing, amount of micrometastasis based off a cfDNA test, and given with this combo tx... I guess for some, they can not see that time...
Indeed, why are things costing so much more in the US over Oz, and yet AU seems to be a significant part of driving the radioligand development/industry...
Prasad would be right.... Big Pharma reaps the profits and we wait on their crumbs like dogs (no offense to you, oh King Of Terror) under the table... We could talk about Prassad's point about using weaker SOC in the control arms to insure a victory lap and a HUGE PAYDAY for Big Pharma, but it makes me want to go take a bite out of Big Pharma...
Chasing cars may have an OS benefit versus getting too deep into Big Pharma's business... you may be Houdini like and disappear... If Prasad vanishes, then line up the usual suspects...
Well, he definitely is not getting many/any invites to speak at research conferences or to dinner by many researchers. Being honest in any endeavor in life can often take one down a very lonely road. However, he probably can count on John Ioannidis to shake his hand and sit on the same podium anywhere they might be welcomed to speak.
"The greatest man is he who chooses right with the most invincible resolution; who resists to sorest temptation from within and without; who bears the heaviest burdens cheerfully; who is calmest in storms, and most fearless under menaces and frowns; whose reliance on truth, on virtue, and on God is most unfaltering."
Such a fabulous statement, and very appropriate for our times... but when on that road, we must not take a short cut or go the lesser path... No !!! Embrace the path and evaluate the possibilities, if one is to hope for attaining the goal !!! Course of action is everything !!!
I hope you are having a nice evening...
BTW--Congrats to UNC for beating WVU in game 1 of the Baseball Super Regional...more tonight...
BTW, I'm more interested in how NCSU is doing . . . 18 to 1 over GA in game one. No need for a walk-off HR by the wolfpack today. I didn't watch either game, but the UNC-WVU game must have been a heart-breaker for you WVU fans. Mountaineers now just have to win the next two. Piece of cake.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
